Are they still the world’s worst drug dealers? – GALE

Soon the world should finally see an earnings release from our favorite purveyor of highly addicitve opiods, and developer of highly suspect cancer vaccines, Galena Biopharma (GALE).

Readers might recall that we examined the sales of Abstral, Galena’s sublingual fentanyl citrate tablets, in this post. We then drilled down into the sales numbers in this post, and discovered that GALE was essentially buying their own product.

So, in anticipation of the upcoming earnings release, lets look at independent sales data for the first two months of 2014.


Galena and the Epsilon Sock Puppets – GALE

A number of comments have recently been submitted for approval to the recent posts on bio-dreck Galena Biopharma (GALE), by commenters “Don Petty” and “Bryce in TX“. [Similar comments have been posted to other articles on other site, like Seeking Alpha, by Don and Bryce as well.]

Both seem to be stubbornly stupid GALE bulls.

It turns out that all 6 comments are from the exact same email address and posted from the same ip address. Nice try.


A Look Inside Their Black Hearts, Part 2 – GALE Edition

Recently, The ran an excellent piece exploring the relationship between bio-dreck Galena Biopharma Inc. (GALE) and a sleazy stock tout shop that goes under many names (DreamTeam Group, MissionIR, Quality Stocks, etc.), you can read it here.

We first ran into this crew during the SEFE promotion in the springtime of 2012. And back then an enterprising reader sent in pictures of the vacant SEFE offices. Read that piece here.

The DTG stock touting swine have removed the disclaimer about GALE from their website, but a captured image was posted on Twitter (see here) and copied below:

Captured Disclaimer on GALE

A BuyersStrike! reader, @FranklinForward made a great suggestion to visit DTG HQ. And so we decided to take a field trip. But to where, exactly?


A Few Words, And A Few Charts, on Galena, World’s Worst Drug Dealers – GALE

Yesterday a post at the Bronte Capital blog pointed out that odious, hyper-promotional, Galena Biopharma (GALE) has a Direct-To-Consumer program that offers a free month of their super-fast-acting fentanyl, which they sell under the brand name Abstral.

Fentanyl is a synthetic opiate drug that is 100 times stronger than morphine and 20 times stronger than diacetylmorphine. What’s diacetylmorphine, you ask?


Naughty Naughty Nanoviricides (NNVC)

Nanoviricides (NNVC), a hype-drenched bio-dreck reverse merged into a shell called, no joke,, is located in leafy New Haven, CT. Run by septugenarian Eugene Seymour, and recently debunked by reporter Teri Buhl (see here and here), NNVC has been touted in the past by the memorable Patrick Cox, and currently by the disgraced Tobin Smith, fired by FOX (see here) over his pumping of Petrosonic Energy (PSON).

Patrick, as many may remember, was one of the Agora stable of “writers”. So it was not a huge surprise to find a reference to Agora in NNVC’s SEC filings.

The text of the filing, however, was a huge surprise. From the July 8, 2013 8K:


Does crime pay? (NCTW, SEFE, Kerrs, Quiels, etc…)

Ever wonder about the finances of penny stock pushers like Steve M. Kerr or Michael L. Quiel? Here’s your chance to satisfy that curiosity, thanks to the PSRs recently released in the USA v Kerr case.

First take a look at Steve Kerr’s, page 18 is pretty telling, looks like over 4mm in profits for 2007’s p&ds:


And then learn all about Quiel, who looks like he has a net worth of about $15mm:


They each made quite a pretty penny, cannot wait to see Humble Harold’s P&L!

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.